Christopher de Souza, PhD
January 29, 2017
Christopher de Souza, PhD, MBA, is a Director at Broadview Ventures. He brings to this role over 30 years of experience in cardiovascular and metabolic related academic research, biopharmaceutical R&D, corporate strategy and business development.
Christopher started his pharmaceutical career at Novartis as a senior scientist in the Metabolic and Cardiovascular Diseases group and then as Director of Strategic Alliances with responsibilities for therapeutic area strategy, business development and alliance management. After Novartis, Christopher was Vice President of Business Development at SkyePharma US Inc., a drug delivery company, where he was responsible for out-licensing the company’s clinical assets and drug delivery technologies.
Christopher received a Masters in zoology from the University of Bombay, a PhD in physiology from Louisiana State University and an MBA from Rutgers University. He completed his post-doctoral training at The Upjohn Company and the Joslin Diabetes Center/Harvard Medical School.
Christopher currently serves on the boards of Acesion, Gila Therapeutics, Mellitus and Pulmokine and previously served on the boards of Allosteros, CellAegis, DecImmune, Herantis, NuPulse, Provasculon and Ventrinova.
Outside of Broadview Ventures, Christopher serves on the board of MassBio and on the grant review committees of the British Heart Foundation and NIH/NHLBI.